¹èÀåÈ£ ¸íÀÇ

¼¼°èÀûÀÎ ÇмúÁö°¡ ÁÖ¸ñÇÏ´Â ÀÇ»ç

¹èÀåÈ£ ¸íÀÇ

  • ¼Ò ¼Ó
    °Ç¾ç´ëº´¿ø ½ÉÀå³»°ú,½ÉÇ÷°ü³»°ú
  • Àü¹®ºÐ¾ß
    °ü»óµ¿¸Æ Áúȯ, ºÎÁ¤¸Æ, ½ÉºÎÀü, ´ëµ¿¸Æ ¹× ¸»ÃÊÇ÷°ü Áúȯ µî

°ü»óµ¿¸ÆÈ®Àå¼ú 6000·Ê ÀÌ»ó, Á¶¿µ¼ú 1¸¸ 5000·Ê ÀÌ»óÀ» ½Ã¼úÇÑ ´ëÀü Áö¿ª ´ëÇ¥ ¸íÀÇ´Ù.
ÁÖ¿ä Áø·á ºÐ¾ß´Â °ü»óµ¿¸ÆÁúȯ, ºÎÁ¤¸Æ, ½ÉºÎÀü, ´ëµ¿¸Æ ¹× ¸»ÃÊÇ÷°üÁúȯÀÌ´Ù. µ¿¸Æ°æÈ­¸¦ Àâ¾Æ¾ß ½ÉÇ÷°ü ÁúȯÀ» ÀâÀ» ¼ö ÀÖ´Ù´Â ¹ÏÀ½À¸·Î µ¿¸Æ°æÈ­ ±âÀüÀ» ÁýÁß ¿¬±¸ÇßÀ¸¸ç, 2000³â¿¡ ¼¼°è ÃÖÃÊ·Î ¡®Áß¼ºÁö¹æÀÌ µ¿¸Æ°æÈ­¿¡ ¹ÌÄ¡´Â ±âÀü¡¯À» ¹àÇô ÀÇÇаèÀÇ ÁÖ¸ñÀ» ¹Þ¾Ò´Ù. ¸Ó¸® ¹× ³ú¿¡ Ç÷¾×À» °ø±ÞÇÏ´Â °æµ¿¸ÆÀÇ µÎ²²°¡ µÎ²¨¿ï¼ö·Ï ½ÉÀåÇ÷°ü ÁúȯÀÇ ¹ß»ý·üÀÌ ³ô¾ÆÁø´Ù´Â ¹è ±³¼öÀÇ ³í¹®Àº, ´ëÇѽÉÀåÇÐȸÀÇ '2018 SCI ÇÇÀοëÁö¼ö ¿ì¼ö»ó'¿¡ ¼±Á¤µÆ´Ù. ÇÇÀοëÁö¼ö ¿ì¼ö»óÀº ´ëÇѽÉÀåÇÐȸÁöÀÎ 'Korean Circulation Journal'¿¡ °ÔÀçµÈ ³í¹® Áß SCI ±Þ ÇмúÁö µî Ÿ ÇмúÁö¿¡ °¡Àå ¸¹ÀÌ ÀοëµÈ ³í¹®¿¡ ÁÖ´Â »óÀÌ´Ù.

¸íÀÇÇÁ·ÎÇÊ ¸íÀÇ ÇÁ·ÎÇÊ

ÇзÂ

Educational Background
  • °è¸í´ëÇб³ ÀÇÇаú ¹Ú»ç
  • °è¸í´ëÇб³ ÀÇÇаú ¼®»ç
  • °è¸í´ëÇб³ ÀÇÇаú Çлç

ÁÖ¿ä°æ·Â

Work Experience
  • úÞ) °Ç¾ç´ëÇб³ Àǹ«ºÎÃÑÀå °â ÀÇ·á¿øÀå
  • úÞ) °Ç¾ç´ëÇб³º´¿ø ½ÉÀå³»°ú ±³¼ö
  • °ü»óµ¿¸ÆÁ¶¿µ¼ú 1¸¸·Ê ÀÌ»ó, °ü»óµ¿¸Æ ½ºÅÙÆ®½Ã¼ú 5õ·Ê ÀÌ»ó, ºÎÁ¤¸Æ ½Ã¼ú 1õ·Ê ÀÌ»ó Áýµµ

¼ö»ó³»¿ª

Awards List
  • ±Þ¼º½É±Ù°æ»ö »ç¸Á·ü ³·Àºº´¿ø Àü±¹ 3À§ (º¸°Çº¹ÁöºÎ)
  • ¼¼°èÀθí»çÀü ¸¶¸£ÄûÁî ÈÄÁîÈÄ 10³â ¿¬¼Ó µîÀç

ÇÐȸȰµ¿

Academic activities
  • 2020 ~ 2022´ëÇѽÉÇ÷°üÁßÀçÇÐȸ ºñ»óÀÓÀÌ»ç
  • 2019 ~ 2022´ëÇѽÉÀåÇÐȸ ¿¬±¸ÀÌ»ç
  • 2018 ~ 2021´ëÇѽÉÇ÷°ü ÁßÀçÇÐȸ ±âȹÀÌ»ç
  • ´ëÇѽÉÀåÇÐȸ °£ÇàÀ§¿ø, Ãѹ«º¸, È«º¸À§¿ø, ¿¬±¸À§¿ø, ´ë¿ÜÇù·ÂÀ§¿ø
  • ±¹°¡º¸ÈÆÃ³ º¸ÈƽɻçÀ§¿øÈ¸ ºñ»óÀÓÁ¤ºÎÀ§¿ø
  • ÁßÀç½Ã¼úÀÎÁõÀÇ ½ÉÃÊÀ½ÆÄ ÀÎÁõÀÇ, ¹Ì±¹½ÉÀåÇÐȸ Á¤È¸¿ø(FACC)
  • ¾Æ½Ã¾ÆÅÂÆò¾çÁßÀç½Ã¼úÀÎÁõÀÇ(FAPSIC), ¹Ì±¹ÁßÀç½Ã¼úȸ¿ø
  • ¾Æ½Ã¾ÆÅÂÆò¾çºÎÁ¤¸Æ½Ã¼úȸ¿ø(FHRS)
Àú¼­ ¾ÆÀÌÄÜ

ÁýÇÊÀú¼­

ÃÑ 0°Ç
¿¬±¸ ¾ÆÀÌÄÜ

ÁÖ¿ä³í¹®

ÃÑ 5°Ç
Á¦ ¸ñ Ten-year clinical outcomes in patients with intermediate coronary stenosis according to the combined culprit lesion
¹ßÇ¥³âµµ 2021 ¹ßÇ¥Áö CLINICAL CARDIOLOGY
Á¦ ¸ñ Toxocariasis-associated acute perimyocarditis with cardiogenic shock: A case report
¹ßÇ¥³âµµ 2021 ¹ßÇ¥Áö American Journal of Case Reports
Á¦ ¸ñ Predictors for high risk carotid plaque in asymptomatic Korean population
¹ßÇ¥³âµµ 2020 ¹ßÇ¥Áö Cardiovascular Therapeutics
Á¦ ¸ñ Efficacy and Safety of dual drug-elutinf stents for de novo coronary lesions in South Korea-The EFFECT Trial
¹ßÇ¥³âµµ 2020 ¹ßÇ¥Áö Journal of Clinical Medicine
Á¦ ¸ñ Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary InterventionThe TAILOR-PCI Randomized Clinical Trial
¹ßÇ¥³âµµ 2020 ¹ßÇ¥Áö JAMA

¸íÀÇqna ¸íÀÇ ¼Ò¼Óº´¿ø

°Ç¾ç´ëº´¿ø

»ó±ÞÁ¾ÇÕº´¿ø
ÀüÈ­ ¾ÆÀÌÄÜ ´ëÇ¥¹øÈ£
1577-3330
À¥»çÀÌÆ® ¾ÆÀÌÄÜȨÆäÀÌÁö

ÁÖ¿ä½Ã¼³

ÀÀ±Þ½Ç ÀÀ±Þ½Ç
Ŭ¸®´Ð Ŭ¸®´Ð
Á¾ÇÕ°ËÁø¼¾ÅÍ Á¾ÇÕ°ËÁø¼¾ÅÍ
¾Ï¼¾ÅÍ ¾Ï¼¾ÅÍ
ÁÖÂ÷½Ã¼³ ÁÖÂ÷½Ã¼³

°Ç¾ç´ëº´¿øÀº 2000³â °³¿øÇÑ Á¾ÇÕ ÀÇ·á±â°üÀ¸·Î º»°ü Áö»ó 11Ãþ ±Ô¸ð¸¦ °®Ãß°í ÀÖ´Ù. ÁßºÎ±Ç ÃÖÃÊ·Î ÀÓ»óº´¸® ÀÚµ¿È­ ½Ã½ºÅÛ, ó¹æ Àü»êÈ­ ÇÁ·Î±×·¥ µîÀ» µµÀÔÇß´Ù. 2011³â 11¿ù ¹®À» ¿¬ ¾Ï¼¾ÅÍ´Â Áö»ó 5Ãþ ±Ô¸ð·Î ¾Ï Á¾·ùº°·Î ¿©·¯ Áø·á°ú°¡ ÇùÁøÇÏ´Â ¾ÏÀü¹®ÆÀ Áø·á ½Ã½ºÅÛÀÌ ¸¶·ÃµÅ ÀÖÀ¸¸ç, º»°ü°ú Á÷Á¢ ¿¬°áµÅ ȯÀÚ ¹× º¸È£ÀÚ°¡ Æí¸®ÇÏ°Ô ÀÌ¿ëÇÒ ¼ö ÀÖ´Ù.

°Ç¾ç´ëº´¿ø À̹ÌÁö

´ëÀü±¤¿ª½Ã ¼­±¸ °üÀúµ¿·Î 158

Ȩ
³»°¡ ¾Ë°íÀÖ´Â ¸íÀǸ¦ ÃßÃµÇØÁÖ¼¼¿ä